REGULAR STRENGTH ANALGESIC & MUSCLE RELAXANT CAPLETS TABLET
Country: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
22-03-2013
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
IBUPROFEN; METHOCARBAMOL
Fáanlegur frá:
TEVA CANADA LIMITED
ATC númer:
M03BA53
INN (Alþjóðlegt nafn):
METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS
Skammtar:
200MG; 500MG
Lyfjaform:
TABLET
Samsetning:
IBUPROFEN 200MG; METHOCARBAMOL 500MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
18/40
Gerð lyfseðils:
OTC
Lækningarsvæði:
CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS
Vörulýsing:
Active ingredient group (AIG) number: 0248961001; AHFS:
Leyfisstaða:
CANCELLED PRE MARKET
Leyfisdagur:
2015-11-25
Vara einkenni
IMPORTANT: PLEASE READ
1 | P a g e
PRODUCT MONOGRAPH
REGULAR STRENGTH ANALGESIC & MUSCLE
RELAXANT CAPLETS
METHOCARBAMOL AND IBUPROFEN TABLETS
500 MG/200 MG
THERAPEUTIC CLASSIFICATION
MUSCLE RELAXANT / ANALGESIC
TEVA CANADA LIMITED,
Date of Preparation:
30 Novopharm Court
March 5, 2013
Toronto, Canada
M1B 2K9
Control# 161027
IMPORTANT: PLEASE READ
2 | P a g e
TABLE
OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..............................................3
SUMMARY PRODUCT INFORMATION
.......................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
..................................................................................................3
ADVERSE
REACTIONS..................................................................................................10
DRUG
INTERACTIONS..................................................................................................12
DOSAGE AND
ADMINISTRATION..............................................................................15
OVERDOSAGE
...............................................................................................................16
ACTION AND CLINICAL PHARMACOLOGY
...........................................................18
STORAGE AND
STABILITY.........................................................................................22
SPECIAL HANDLING INSTRUCTIONS
......................................................................22
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................22
PART II: SCIENTIFIC
INFORMATION....................................................................21
PHARMACEUTICAL
INFORMATION..........................................................................21
CLINICAL
TRIALS..........................................................................................................23
DETAILED
PHARMACOLOGY........................................
Lestu allt skjalið
